Loading...
Loading...
TALS| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 18.4M |
| Operating I/L | -18.4M |
| Other Income/Expense | 0.2M |
| Interest Income | 0.0M |
| Pretax | -18.3M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -18.3M |
Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company focused on developing allogeneic hematopoietic stem cell transplantation for solid organ transplantation, severe autoimmune diseases, and non-malignant blood, immune, and metabolic disorders. Its lead product, FCR001, is a novel allogeneic cell therapy in Phase II trial for living donor kidney transplant patients. The company also works on FCR002 for deceased donor kidney transplants, FCR001 for severe scleroderma, and FCR001 for severe non-malignant blood, immune, or metabolic disorders.
